Hematoma regression: a therapeutic target for intracerebral hemorrhage
10.3760/cma.j.issn.1673-4165.2022.08.013
- VernacularTitle:血肿消退：脑出血的治疗靶点
- Author:
Chong ZHANG
1
;
Jincheng MENG
;
Sinan JIN
;
Wei HUA
;
He WU
Author Information
1. 哈尔滨医科大学附属第一医院病理科，哈尔滨 150001
- Keywords:
Cerebral hemorrhage;
Hematoma;
Microglia;
Macrophages;
Phagocytosis
- From:
International Journal of Cerebrovascular Diseases
2022;30(8):631-635
- CountryChina
- Language:Chinese
-
Abstract:
The disability and mortality rate of patients with intracerebral hemorrhage are very high. At present, there is no effective treatment to improve the outcome of patients with intracerebral hemorrhage. Mechanical compression of hematoma and release of toxic products are the main causes of primary and secondary brain injury in patients with intracerebral hemorrhage, while safe and effective acceleration of hematoma regression is the key strategy to improve the neurological deficit in patients with intracerebral hemorrhage. Microglia/macrophages are the main phagocytic system that mediates hematoma clearance and are mainly polarized into M1 and M2 phenotypes. Cell surface receptors and possible signal transduction pathways play an important role in regulating the endogenous hematoma regression mediated by microglia/macrophages, and may become a new target for clinical treatment of intracerebral hemorrhage and improvement of the outcomes of patients in the future.
